Events
-
-
ENDO 2026: Women’s thyroid cancer risk may be linked to reproductive lifespan and hormone therapy
-
ASCO 2026: Lancet Commission predict shortfall of 100 million cancer care workers by 2050
-
ASCO 2026: CAPTURE trial delivers learnings for metastatic breast cancer treatment
-
ASCO 2026: Teclistamab extends survival, deepens remissions in relapsed multiple myeloma
-
ASCO 2026: Lancet Commission predict shortfall of 100 million cancer care workers by 2050
-
-
ASCO 2026: Teclistamab extends survival, deepens remissions in relapsed multiple myeloma
-
-
Contagious cancer likely crossed an ocean, triggering severe outbreak in Pacific Northwest clams
Researchers have identified a severe outbreak of a rare contagious cancer in soft-shell clams in…
REVITALIZE study to evaluate laser therapy for vaginal dryness after breast cancer treatment
The Alliance for Clinical Trials in Oncology is now enrolling patients into a clinical trial…
AACR 2026: Exposure to wildfire smoke may be linked to increased risk of developing several cancers
Exposure to wildfire smoke was associated with a significantly increased risk of lung, colorectal, breast,…
Rise in colorectal cancer among young adults in Germany as well — but below US levels
- ASCO 2026: EMERALD-3 study shows that new combination treatment strategies for embolization-eligible hepatocellular carcinoma are superior
- ASCO 2026: Phase 3 PEAK study could usher in new second-line therapy for GIST
- AACR 2026: Sleep deprivation disrupts gut microbiota, worsening colorectal cancer outcomes
S4 E5: ASCO 2026 Special Part 2
ASCO Special Part 2: Quick Bite Marathon! The Oncology Journal Club Podcast hosted by Professor Craig Underhill, Dr Kate Clarke…
Chemoimmunotherapy linked to improved survival in PD-L1-high NSCLC meta-analysis
- ASCO 2026: Selpercatinib shows decrease in risk of disease recurrence or death as adjuvant therapy for early-stage RET fusion-positive NSCLC
- AACR 2026: Investigational KRAS(ON) inhibitor zoldonrasib showed effective and durable responses in patients with advanced G12D-mutated lung cancer
- AACR 2026: Next-generation KRAS G12C inhibitor elisrasib elicited promising response rates in patients with advanced lung cancer
Culture, silence and safety: why oncology cannot afford to ignore its workforce
By Dr Dominique Lee Public trust in oncology relies on strong professional standards, transparent governance, and confidence that concerns will be…
JOIN THE ONCOLOGY NETWORK
If you would like even more free news articles, access to our exclusive HCP only content including the latest podcasts from The Oncology Podcast and our Industry Partner Podcasts (including links to all papers and show notes), along with all our other resources, head over to The Oncology Network and sign up - FREE forever for HCPs only.